California 2025-2026 Regular Session

California Assembly Bill AB1320 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	CALIFORNIA LEGISLATURE 20252026 REGULAR SESSION Assembly Bill No. 1320Introduced by Assembly Member PattersonFebruary 21, 2025 An act to add Section 127698 to the Health and Safety Code, relating to public contracts. LEGISLATIVE COUNSEL'S DIGESTAB 1320, as introduced, Patterson. California Affordable Drug Manufacturing Act of 2020: opioid antagonists.Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships, in consultation with other state departments as necessary, to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. For purposes of implementing these provisions, existing law authorizes CHHSA and its departments, including the Department of Health Care Access and Information, to enter into exclusive or nonexclusive contracts on a bid or negotiated bases. Existing law exempts these contracts entered into by CHHSA and its departments from the review or approval of any division of the Department of General Services as well as from provisions pertaining to bidding and awarding of state contracts.This bill would prohibit a state agency from awarding a contract, pursuant to the above provisions, on a noncompetitive basis for the purchase or acquisition of an opioid antagonist, as defined, with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic. The bill would make a contract void and unenforceable for a violation of this provision and apply those provisions retroactively to contracts entered into before January 1, 2026.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO Bill TextThe people of the State of California do enact as follows:SECTION 1. Section 127698 is added to the Health and Safety Code, to read:127698. (a) Notwithstanding Section 127692, a state agency shall not, pursuant to this chapter, award a contract on a noncompetitive basis for the purchase or acquisition of an opioid antagonist with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic.(b) A contract is void and unenforceable if it violates this section.(c) This section shall apply retroactively to any contract entered into before January 1, 2026.(d) For purposes of this section, opioid antagonist means naloxone hydrochloride or another drug approved by the United States Food and Drug Administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body, and has been approved for the treatment of an opioid overdose.
2	2
3	3	CALIFORNIA LEGISLATURE 20252026 REGULAR SESSION Assembly Bill No. 1320Introduced by Assembly Member PattersonFebruary 21, 2025 An act to add Section 127698 to the Health and Safety Code, relating to public contracts. LEGISLATIVE COUNSEL'S DIGESTAB 1320, as introduced, Patterson. California Affordable Drug Manufacturing Act of 2020: opioid antagonists.Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships, in consultation with other state departments as necessary, to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. For purposes of implementing these provisions, existing law authorizes CHHSA and its departments, including the Department of Health Care Access and Information, to enter into exclusive or nonexclusive contracts on a bid or negotiated bases. Existing law exempts these contracts entered into by CHHSA and its departments from the review or approval of any division of the Department of General Services as well as from provisions pertaining to bidding and awarding of state contracts.This bill would prohibit a state agency from awarding a contract, pursuant to the above provisions, on a noncompetitive basis for the purchase or acquisition of an opioid antagonist, as defined, with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic. The bill would make a contract void and unenforceable for a violation of this provision and apply those provisions retroactively to contracts entered into before January 1, 2026.Digest Key Vote: MAJORITY Appropriation: NO Fiscal Committee: YES Local Program: NO
4	4
5	5
6	6
7	7
8	8
9	9	CALIFORNIA LEGISLATURE 20252026 REGULAR SESSION
10	10
11	11	Assembly Bill
12	12
13	13	No. 1320
14	14
15	15	Introduced by Assembly Member PattersonFebruary 21, 2025
16	16
17	17	Introduced by Assembly Member Patterson
18	18	February 21, 2025
19	19
20	20	An act to add Section 127698 to the Health and Safety Code, relating to public contracts.
21	21
22	22	LEGISLATIVE COUNSEL'S DIGEST
23	23
24	24	## LEGISLATIVE COUNSEL'S DIGEST
25	25
26	26	AB 1320, as introduced, Patterson. California Affordable Drug Manufacturing Act of 2020: opioid antagonists.
27	27
28	28	Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships, in consultation with other state departments as necessary, to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. For purposes of implementing these provisions, existing law authorizes CHHSA and its departments, including the Department of Health Care Access and Information, to enter into exclusive or nonexclusive contracts on a bid or negotiated bases. Existing law exempts these contracts entered into by CHHSA and its departments from the review or approval of any division of the Department of General Services as well as from provisions pertaining to bidding and awarding of state contracts.This bill would prohibit a state agency from awarding a contract, pursuant to the above provisions, on a noncompetitive basis for the purchase or acquisition of an opioid antagonist, as defined, with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic. The bill would make a contract void and unenforceable for a violation of this provision and apply those provisions retroactively to contracts entered into before January 1, 2026.
29	29
30	30	Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency (CHHSA) or its departments to enter into partnerships, in consultation with other state departments as necessary, to increase competition, lower prices, and address shortages in the market for generic prescription drugs, to reduce the cost of prescription drugs for public and private purchasers, taxpayers, and consumers, and to increase patient access to affordable drugs. For purposes of implementing these provisions, existing law authorizes CHHSA and its departments, including the Department of Health Care Access and Information, to enter into exclusive or nonexclusive contracts on a bid or negotiated bases. Existing law exempts these contracts entered into by CHHSA and its departments from the review or approval of any division of the Department of General Services as well as from provisions pertaining to bidding and awarding of state contracts.
31	31
32	32	This bill would prohibit a state agency from awarding a contract, pursuant to the above provisions, on a noncompetitive basis for the purchase or acquisition of an opioid antagonist, as defined, with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic. The bill would make a contract void and unenforceable for a violation of this provision and apply those provisions retroactively to contracts entered into before January 1, 2026.
33	33
34	34	## Digest Key
35	35
36	36	## Bill Text
37	37
38	38	The people of the State of California do enact as follows:SECTION 1. Section 127698 is added to the Health and Safety Code, to read:127698. (a) Notwithstanding Section 127692, a state agency shall not, pursuant to this chapter, award a contract on a noncompetitive basis for the purchase or acquisition of an opioid antagonist with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic.(b) A contract is void and unenforceable if it violates this section.(c) This section shall apply retroactively to any contract entered into before January 1, 2026.(d) For purposes of this section, opioid antagonist means naloxone hydrochloride or another drug approved by the United States Food and Drug Administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body, and has been approved for the treatment of an opioid overdose.
39	39
40	40	The people of the State of California do enact as follows:
41	41
42	42	## The people of the State of California do enact as follows:
43	43
44	44	SECTION 1. Section 127698 is added to the Health and Safety Code, to read:127698. (a) Notwithstanding Section 127692, a state agency shall not, pursuant to this chapter, award a contract on a noncompetitive basis for the purchase or acquisition of an opioid antagonist with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic.(b) A contract is void and unenforceable if it violates this section.(c) This section shall apply retroactively to any contract entered into before January 1, 2026.(d) For purposes of this section, opioid antagonist means naloxone hydrochloride or another drug approved by the United States Food and Drug Administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body, and has been approved for the treatment of an opioid overdose.
45	45
46	46	SECTION 1. Section 127698 is added to the Health and Safety Code, to read:
47	47
48	48	### SECTION 1.
49	49
50	50	127698. (a) Notwithstanding Section 127692, a state agency shall not, pursuant to this chapter, award a contract on a noncompetitive basis for the purchase or acquisition of an opioid antagonist with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic.(b) A contract is void and unenforceable if it violates this section.(c) This section shall apply retroactively to any contract entered into before January 1, 2026.(d) For purposes of this section, opioid antagonist means naloxone hydrochloride or another drug approved by the United States Food and Drug Administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body, and has been approved for the treatment of an opioid overdose.
51	51
52	52	127698. (a) Notwithstanding Section 127692, a state agency shall not, pursuant to this chapter, award a contract on a noncompetitive basis for the purchase or acquisition of an opioid antagonist with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic.(b) A contract is void and unenforceable if it violates this section.(c) This section shall apply retroactively to any contract entered into before January 1, 2026.(d) For purposes of this section, opioid antagonist means naloxone hydrochloride or another drug approved by the United States Food and Drug Administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body, and has been approved for the treatment of an opioid overdose.
53	53
54	54	127698. (a) Notwithstanding Section 127692, a state agency shall not, pursuant to this chapter, award a contract on a noncompetitive basis for the purchase or acquisition of an opioid antagonist with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic.(b) A contract is void and unenforceable if it violates this section.(c) This section shall apply retroactively to any contract entered into before January 1, 2026.(d) For purposes of this section, opioid antagonist means naloxone hydrochloride or another drug approved by the United States Food and Drug Administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body, and has been approved for the treatment of an opioid overdose.
55	55
56	56
57	57
58	58	127698. (a) Notwithstanding Section 127692, a state agency shall not, pursuant to this chapter, award a contract on a noncompetitive basis for the purchase or acquisition of an opioid antagonist with a contractor that has entered into a multistate settlement agreement for its role in contributing to the opioid epidemic.
59	59
60	60	(b) A contract is void and unenforceable if it violates this section.
61	61
62	62	(c) This section shall apply retroactively to any contract entered into before January 1, 2026.
63	63
64	64	(d) For purposes of this section, opioid antagonist means naloxone hydrochloride or another drug approved by the United States Food and Drug Administration that, when administered, negates or neutralizes in whole or in part the pharmacological effects of an opioid in the body, and has been approved for the treatment of an opioid overdose.